Rhenman & Partners Asset Management Ab Summit Therapeutics Inc. Call Options Transaction History
Rhenman & Partners Asset Management Ab
- $766 Million
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SMMT
# of Institutions
272Shares Held
90.9MCall Options Held
4.71MPut Options Held
3.17M-
Baker Bros. Advisors LP New York, NY33.7MShares$591 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.67MShares$152 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$138 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$70.4 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$68.4 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.53B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...